"I didn't say Sirtex was exactly comparable, I used it as an...

"I didn't say Sirtex was exactly comparable, I used it as an example of how disappointing clinical trials will not necessarily result in delisting of the stock and shareholders losing everything."

Your example is PLAIN INCORRECT.

Sirtex product for last of line treatment is a revenue generating product growing at 20% per annum. The fact that the product is not proven for first line use in clinical trials does not affect that.

MSB has NO revenue generating product, and if they continue not to have a revenue generating product, there is only one logical conclusion.

And based on the above, yes, my claim is that there is a possibility for MSB investors to lose the lot. We can debate on the degree of probabilities, but the probability of zero for MSB is not zero.